Icotyde (icotrokinra)

One-Year Data Reinforces Icotyde’s Position as Transformative Psoriasis Therapy: Sustained Clearance and Favorable Safety Profile

One-Year Data Reinforces Icotyde’s Position as Transformative Psoriasis Therapy: Sustained Clearance and Favorable Safety Profile

Johnson & Johnson announced promising long-term efficacy and safety data for Icotyde (icotrokinra), the first and only targeted oral peptide that precisely blocks the IL-23 receptor for plaque psoriasis treatment.…

Continue Reading One-Year Data Reinforces Icotyde’s Position as Transformative Psoriasis Therapy: Sustained Clearance and Favorable Safety Profile
We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.
Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Partner With Us
Submit a Story

Keep Up to Date

Subscribe to Our Newsletter
Check Out Rare Events
Get Inspired By Our Memes

Learn More

About Us
Rare Diseases and Conditions
Terms of Use
Privacy Notice
Privacy Policy for CA Residents
EU/UK Privacy Notice
Data Privacy Framework: Consumer Privacy Policy
Consumer Health Data Privacy Policy
Cookie Notice

Facebook-f Twitter Instagram Podcast Youtube Tiktok Linkedin-in Pinterest Envelope

© Copyright 2024 Patient Worthy